Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 VALUE CHAIN ANALYSIS
15 HEALTHCARE ECONOMY
15.1 HEALTHCARE EXPENDITURE
15.2 CAPITAL EXPENDITURE
15.3 CAPEX TRENDS
15.4 CAPEX ALLOCATION
15.5 FUNDING SOURCES
15.6 INDUSTRY BENCHMARKS
15.7 GDP RATION IN OVERALL GDP
15.8 HEALTHCARE SYSTEM STRUCTURE
15.9 GOVERNMENT POLICIES
15.1 ECONOMIC DEVELOPMENT
16 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET , BY PRODUCT
16.1 OVERVIEW
16.2 PACEMAKERS
16.2.1 BY TYPE
16.2.1.1. SINGLE CHAMBER
16.2.1.2. DUAL CHMABER
16.2.1.3. BIVENTRICULAR PACEMAKERS
16.2.2 BY COMPATIBILITY
16.2.2.1. MRI COMPATIBLE
16.2.2.2. NON-MRI COMPATIBLE
16.2.3 BY SYTEM TYPE
16.2.3.1. LEADED SYSTEM
16.2.3.1.1. TRANSVENOUS SYSTEMS
16.2.3.1.2. EPICARDIAL SYSTEMS
16.2.3.2. LEADLESS SYSTEMS
16.2.4 BY BRAND
16.2.4.1. MICRA TRANSCATHETER PACING SYSTEM
16.2.4.2. AVEIR (VR) WIRELESS PACEMAKER SYSTEM
16.2.4.3. WISE CRT SYSTEM
16.2.4.4. OTHERS
16.2.5 OTHERS
16.3 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD)
16.3.1 BY TYPE
16.3.1.1. SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (S-ICDS)
16.3.1.1.1. PULSE GENERATOR
16.3.1.1.1.1 TITANIUM
16.3.1.1.1.2 RIGID POLYURETHANE
16.3.1.1.1.3 OTHERS
16.3.1.1.2. LEADS
16.3.1.1.2.1 SOFT POLYURETHANE
16.3.1.1.2.2 SILICONE
16.3.1.1.2.3 OTHERS
16.3.1.1.3. OTHERS
16.3.1.2. TRANSVENOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (T-ICDS)
16.3.1.2.1. BIVENTRICULAR ICDS
16.3.1.2.1.1 PULSE GENERATOR
16.3.1.2.1.1.1. TITANIUM
16.3.1.2.1.1.2. RIGID POLYURETHANE
16.3.1.2.1.1.3. OTHERS
16.3.1.2.1.2 LEADS
16.3.1.2.1.2.1. SOFT POLYURETHANE
16.3.1.2.1.2.2. SILICONE
16.3.1.2.1.2.3. OTHERS
16.3.1.2.1.3 OTHERS
16.3.1.2.2. DUAL-CHAMBER ICDS
16.3.1.2.2.1 PULSE GENERATOR
16.3.1.2.2.1.1. TITANIUM
16.3.1.2.2.1.2. RIGID POLYURETHANE
16.3.1.2.2.1.3. OTHERS
16.3.1.2.2.2 LEADS
16.3.1.2.2.2.1. SOFT POLYURETHANE
16.3.1.2.2.2.2. SILICONE
16.3.1.2.2.2.3. OTHERS
16.3.1.2.2.3 OTHERS
16.3.1.2.3. SINGLE-CHAMBER ICDS
16.3.1.2.3.1 PULSE GENERATOR
16.3.1.2.3.1.1. TITANIUM
16.3.1.2.3.1.2. RIGID POLYURETHANE
16.3.1.2.3.1.3. OTHERS
16.3.1.2.3.2 LEADS
16.3.1.2.3.2.1. SOFT POLYURETHANE
16.3.1.2.3.2.2. SILICONE
16.3.1.2.3.2.3. OTHERS
16.3.1.2.3.3 OTHERS
16.3.2 BY TECHNOLOGY
16.3.2.1. TRADITIONAL
16.3.2.2. SUBCUTANEOUS
16.3.3 OTHERS
16.4 CARDIAC RESYNCHRONIZATION THERAPY (CRT)
16.4.1 BY TYPE
16.4.1.1. CARDIAC RESYNCHRONIZATION THERAPY DEFIBRILLATOR
16.4.1.1.1. MRI COMPATIBLE CRT-P DEVICES
16.4.1.1.2. CONVENTIONAL CRT-P DEVICES
16.4.1.2. CARDIAC RESYNCHRONIZATION THERAPY PACEMAKER
16.4.1.2.1. MRI COMPATIBLE CRT-P DEVICES
16.4.1.2.2. CONVENTIONAL CRT-P DEVICES
16.4.2 BY COMPONENT
16.4.2.1. DEVICE
16.4.2.2. LEAD
16.4.3 OTHERS
16.5 OTHERS
17 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET , BY TECHNOLOGY
17.1 OVERVIEW
17.2 WIRELESS IMPLANTABLE DEVICES
17.3 MRI-COMPATIBLE DEVICES
17.4 CONVENTIONAL DEVICES
17.5 OTHERS
18 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET , BY USAGE
18.1 OVERVIEW
18.2 PERMANENT IMPLANTATION
18.3 TEMPORARY IMPLANTATION
19 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET , BY PROCEDURE
19.1 OVERVIEW
19.2 TRANSVENOUS IMPLANTATION
19.3 SUBCUTANEOUS IMPLANTATION
19.4 EPICARDIAL IMPLANTATION
19.5 OTHERS
20 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET , BY AGE GROUP
20.1 OVERVIEW
20.2 PEDIATRIC
20.3 ADULT
20.4 GERIATRIC
21 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET , BY APPLICATION
21.1 OVERVIEW
21.2 ARRHYTHMIAS
21.2.1 PACEMAKERS
21.2.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD)
21.2.3 CARDIAC RESYNCHRONIZATION THERAPY (CRT)
21.3 BRADYCARDIA
21.3.1 PACEMAKERS
21.3.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD)
21.3.3 CARDIAC RESYNCHRONIZATION THERAPY (CRT)
21.4 TACHYCARDIA
21.4.1 PACEMAKERS
21.4.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD)
21.4.3 CARDIAC RESYNCHRONIZATION THERAPY (CRT)
21.5 HERAT FAILURE
21.5.1 PACEMAKERS
21.5.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD)
21.5.3 CARDIAC RESYNCHRONIZATION THERAPY (CRT)
21.6 MYOCARDIAL INFARCTION
21.6.1 PACEMAKERS
21.6.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD)
21.6.3 CARDIAC RESYNCHRONIZATION THERAPY (CRT)
21.7 CORONARY ARTERY DISEASE
21.7.1 PACEMAKERS
21.7.2 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD)
21.7.3 CARDIAC RESYNCHRONIZATION THERAPY (CRT)
21.8 OTHER (IF ANY)
22 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET , BY END USER
22.1 OVERVIEW
22.2 HOSPITALS
22.2.1 BY TYPE
22.2.2 PUBLIC
22.2.3 PRIVATE
22.2.4 BY LEVEL
22.2.5 TIER 1
22.2.6 TIER 2
22.2.7 TIER 3
22.3 CATH LABS
22.3.1 PUBLIC
22.3.2 PRIVATE
22.4 SPECIALTY CENTERS
22.4.1 PUBLIC
22.4.2 PRIVATE
22.5 AMBULATORY SURGERY CENTERS
22.6 ACADEMIC AND RESEARCH CENTRES
22.7 OTHERS
23 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET , BY DISTRIBUTION CHANNEL
23.1 OVERVIEW
23.2 DIRECT TENDER
23.3 RETAIL SALES
23.3.1 ONLINE SALES
23.3.2 OFFLINE SALES
23.3.3 THIRD PARTY DISTRIBUTION
23.4 OTHERS
24 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET , BY GEOGRAPHY
24.1 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.1.1 NORTH AMERICA
24.1.1.1. U.S.
24.1.1.2. CANADA
24.1.1.3. MEXICO
24.1.2 EUROPE
24.1.2.1. GERMANY
24.1.2.2. FRANCE
24.1.2.3. U.K.
24.1.2.4. ITALY
24.1.2.5. SPAIN
24.1.2.6. RUSSIA
24.1.2.7. TURKEY
24.1.2.8. NETHERLANDS
24.1.2.9. SWITZERLAND
24.1.2.10. REST OF EUROPE
24.1.3 ASIA-PACIFIC
24.1.3.1. JAPAN
24.1.3.2. CHINA
24.1.3.3. SOUTH KOREA
24.1.3.4. INDIA
24.1.3.5. AUSTRALIA
24.1.3.6. SINGAPORE
24.1.3.7. THAILAND
24.1.3.8. MALAYSIA
24.1.3.9. INDONESIA
24.1.3.10. PHILIPPINES
24.1.3.11. REST OF ASIA-PACIFIC
24.1.4 SOUTH AMERICA
24.1.4.1. BRAZIL
24.1.4.2. ARGENTINA
24.1.4.3. REST OF SOUTH AMERICA
24.1.5 MIDDLE EAST AND AFRICA
24.1.5.1. SOUTH AFRICA
24.1.5.2. SAUDI ARABIA
24.1.5.3. UAE
24.1.5.4. EGYPT
24.1.5.5. ISRAEL
24.1.5.6. REST OF MIDDLE EAST AND AFRICA
24.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET , COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: GLOBAL
25.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
25.3 COMPANY SHARE ANALYSIS: EUROPE
25.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
25.5 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
25.6 MERGERS & ACQUISITIONS
25.7 NEW PRODUCT DEVELOPMENT & APPROVALS
25.8 EXPANSIONS
25.9 REGULATORY CHANGES
25.1 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
26 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET , SWOT AND DBR ANALYSIS
27 GLOBAL IMPLANTABLE CARDIAC RHYTHM MANAGEMENT MARKET , COMPANY PROFILE
27.1 ABBOTT
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPMENTS
27.2 MEDTRONIC
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPMENTS
27.3 BOSTON SCIENTIFIC CORPORATION OR ITS AFFILIATES
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPMENTS
27.4 LEPU MEDICAL TECHNOLOGY(BEIJING)CO.,LTD.
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPMENTS
27.5 BIOTRONIK
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPMENTS
27.6 PURPLE MICROPORT
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPMENTS
27.7 MEDICO SRL
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPMENTS
27.8 VITATRON HOLDING B.V.
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPMENTS
27.9 CAIRDAC
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPMENTS
27.1 LIVANOVA PLC + MICROPORT SCIENTIFIC CORPORATION
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPMENTS
27.11 CAMERON HEALTH INC.
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPMENTS
27.12 SHREE PACETRONIX LTD.
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPMENTS
27.13 DONATELLE
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPMENTS
27.14 MEDIVED INNOVATIONS PVT LTD
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPMENTS
27.15 EBR SYSTEMS, INC.
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST RELATED REPORTS
28 RELATED REPORT
29 CONCLUSION
30 QUESTIONNAIRE
31 ABOUT DATA BRIDGE MARKET RESEARCH
